연속 혈당 모니터링 시스템 시장 : 기술, 제품, 최종사용자, 유통 채널, 용도별 - 세계 예측(2025-2032년)

The Continuous Blood Glucose Monitoring Systems Market is projected to grow by USD 9.27 billion at a CAGR of 8.38% by 2032.

Introduce the dynamics and clinical evolution of continuous glucose monitoring technologies that are redefining diabetes care pathways and stakeholder expectations

Continuous blood glucose monitoring systems have evolved from niche clinical tools into foundational enablers of modern diabetes care, bridging the gap between intermittent self-monitoring and continuous physiological insight. These systems combine sensor hardware, data management platforms, and interoperable transmitters to deliver near-real-time glucose trends and predictive alerts, which clinicians and patients increasingly rely upon to personalize therapy and reduce acute glycemic events.

Recent device iterations emphasize miniaturization, sensor longevity, and user-centric design, reducing friction for long-term adherence. Meanwhile, software-driven analytics and cloud connectivity have transformed raw glucose readings into actionable guidance, enabling remote monitoring, telemedicine integration, and population-level analytics that inform clinical workflows. This convergence of hardware and software is reshaping care pathways, as primary care providers, endocrinologists, and multidisciplinary teams incorporate continuous data streams into routine practice.

Regulatory bodies have clarified pathways for integrated devices and software as medical devices, prompting manufacturers to align design controls, clinical evidence generation, and cybersecurity safeguards. At the same time, healthcare payers and procurement groups are paying closer attention to real-world outcomes and reimbursement evidence, prompting broader discussions about value-based contracting. Transitioning from episodic testing to continuous monitoring requires adjustments to clinical protocols, patient education, and supply chain planning, but promises improved glycemic control and reduced burden for many patients.

As stakeholders adopt these systems, market dynamics are increasingly shaped by strategic partnerships across medical device firms, digital health vendors, and distribution networks that facilitate product accessibility and clinician training. These alliances are fundamental to scaling adoption and ensuring that continuous monitoring contributes meaningfully to patient-centered diabetes management.

Examine the converging technological, regulatory, and care delivery shifts that are accelerating adoption and reshaping competitive differentiation in CGM

The landscape for continuous blood glucose monitoring is undergoing transformative shifts driven by technological integration, regulatory evolution, and changes in care delivery models. Sensor accuracy improvements and extended wear profiles have expanded eligibility beyond tightly controlled clinic settings, enabling broader adoption across ambulatory and home care environments. Concomitantly, advances in wireless telemetry and low-power electronics have enabled seamless connectivity between sensors, transmitters, and cloud-based analytics platforms, expanding the utility of continuous data for both patients and clinicians.

A second notable shift is the rise of software-centric differentiation. Algorithms that convert glucose traces into predictive alerts, insulin dosing suggestions, and population-level insights are now central to product value propositions. This has turned software development and regulatory compliance for digital features into strategic priorities for device manufacturers. Moreover, interoperability with electronic health records and third-party digital therapeutics has created new expectations for data portability and integrated care pathways.

Third, reimbursement and care delivery transformations have altered adoption dynamics. Payer policies that recognize the clinical value of continuous monitoring, alongside remote patient monitoring reimbursement, have encouraged clinicians to prescribe these systems more readily. This has been especially relevant for complex patients and care settings where continuous data reduces hospital readmissions and emergency interventions. Meanwhile, shifting supply chain strategies and regional manufacturing initiatives are reshaping sourcing decisions, with manufacturers balancing resilience, cost, and compliance concerns.

Finally, patient empowerment and behavioral change models are influencing product design. Devices that minimize maintenance, offer simplified onboarding, and integrate into daily routines are showing higher persistence rates. The cumulative effect of these trends is a market that prizes ecosystem compatibility, evidence generation, and user experience as much as raw technical performance.

Analyze how tariff adjustments on medical device components are prompting supply chain redesign, cost management strategies, and regional manufacturing shifts in 2025

The imposition and recalibration of tariffs on medical devices and components originating from certain jurisdictions have prompted a reassessment of cross-border sourcing and pricing strategies in 2025. Tariff changes increase the cost of imported sensors, transmitters, and subcomponents, driving manufacturers to evaluate sourcing alternatives, nearshoring strategies, and vertical integration to protect margins. These supply chain adjustments often lead to reconfigured supplier agreements and longer lead times as organizations certify new vendors or expand domestic manufacturing capabilities.

Procurement groups and hospital systems respond by renegotiating contracts and seeking bundled offerings that offset increased unit costs through service-level efficiencies or extended warranties. Manufacturers must decide whether to absorb incremental costs to maintain competitive list prices or to pass costs through to customers, each choice influencing market competitiveness and adoption rates. In some instances, companies accelerate investment in automation and localization initiatives to reduce exposure to tariff volatility and improve supply resilience.

Regulatory and customs compliance burdens also increase administrative overhead, as product registrations, country-of-origin documentation, and tariff classification disputes require dedicated resources. Smaller suppliers and new entrants may find these barriers onerous, which can consolidate market preference toward established firms with diversified manufacturing footprints. Meanwhile, strategic pricing adjustments, such as segment-specific pricing and differentiated channel strategies, can mitigate some near-term impacts, while long-term responses include partnerships with contract manufacturers and investments in regional production hubs.

Ultimately, the cumulative effect of tariff-driven cost pressures stimulates both defensive and proactive strategic moves across the value chain. Stakeholders focused on continuity of supply and cost management will favor flexible sourcing arrangements, stronger distributor relationships, and investments in operational efficiencies to preserve access and value for patients and providers.

Deliver detailed segmentation intelligence across technology, product, end user, distribution channel, and application that illuminates differentiated demand dynamics and operational priorities

A nuanced view of product and service segmentation reveals distinct demand drivers and operational considerations across technology modalities, product types, end-user settings, distribution channels, and clinical applications. In terms of technology, the market differentiates between real-time continuous glucose monitoring systems and retrospective systems; real-time offerings further split into personal on-body systems optimized for daily self-management and professional real-time systems designed for clinician-led monitoring and episodic diagnostic use, while retrospective systems are predominantly professional tools used for data-rich clinical assessment and therapeutic titration.

Product segmentation underscores that data management software and support services have become as critical as sensors and transmitters in delivering clinical value. Within software and services, standalone analytics platforms and ongoing technical support services facilitate data interpretation and integration into care pathways. Hardware segmentation includes sensors, which form the primary interface with physiology, and transmitter and receiver systems; the latter category separates into receivers used for display and data retrieval, and transmitters that securely relay sensor signals and enable cloud connectivity.

End-user segmentation highlights diverse adoption patterns across ambulatory care centers, home care environments, and hospitals and clinics. Ambulatory settings encompass diagnostic centers and surgery centers that use monitoring for perioperative and diagnostic applications, while hospitals and clinics split into outpatient clinics and inpatient hospital settings where continuous data supports intensive care and inpatient glucose management. Home care adoption is driven by ease of use, supply logistics, and patient education frameworks that promote long-term adherence.

Distribution channel insights show a mix of hospital pharmacies, online pharmacies, and retail pharmacies with each channel requiring tailored commercial approaches; online pharmacy channels include e-commerce platforms and manufacturer-direct websites that facilitate subscription services, whereas retail distribution comprises chain and independent pharmacies that emphasize local access and point-of-care counseling. Application segmentation continues to prioritize distinct clinical populations, with usage patterns separating gestational diabetes, type 1 diabetes, and type 2 diabetes, each presenting unique clinical management needs and policy considerations.

Reveal how regional differences in reimbursement, regulatory rigor, and healthcare delivery systems affect commercialization and adoption across Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption patterns, reimbursement frameworks, and competitive strategies in distinct ways across the Americas, Europe Middle East and Africa, and Asia-Pacific regions. In the Americas, health systems show strong appetite for integrated monitoring solutions that support remote care models and value-based initiatives; private and public payers are increasingly focused on real-world evidence to justify broader coverage, while distribution networks prioritize fast replenishment and patient training resources that support home use.

Within Europe, the Middle East, and Africa, regulatory complexity and heterogeneous reimbursement environments create both opportunities and barriers. Western European markets often emphasize clinical evidence and interoperability standards, encouraging devices that integrate with electronic health records and meet stringent data protection requirements. In contrast, markets within the Middle East and Africa may prioritize cost-effectiveness and supply chain reliability, which escalates the importance of localized partnerships and channel strategies adapted to variable procurement processes.

Asia-Pacific exhibits a varied landscape characterized by high-volume public procurement in some jurisdictions, rapid digital health adoption in urban centers, and growing domestic manufacturing capabilities. Several markets in the region have prioritized regulatory harmonization and local capacity-building, which enhances the business case for regional manufacturing and strategic alliances. Across all regions, cultural attitudes toward self-care, the maturity of telehealth ecosystems, and the structure of pharmacy and hospital distribution networks significantly influence product positioning and commercialization tactics.

Provide insight into how manufacturers, software innovators, component suppliers, and distribution partners align strategies to shape competitive advantage and ecosystem value

Industry participants include an ecosystem of device manufacturers, software developers, component suppliers, contract manufacturers, and distribution partners whose strategies shape competitive dynamics. Broadly, leading device manufacturers emphasize integrated platform strategies that combine high-fidelity sensors with robust connectivity and proprietary analytics; these firms invest heavily in clinical validation and regulatory compliance to maintain product differentiation and clinician trust.

Software vendors and analytics firms increasingly become strategic partners, providing cloud-hosted platforms, predictive algorithms, and interoperability layers that expand the functional breadth of monitoring systems. Component suppliers focus on innovations in biocompatible materials, electrode chemistry, and low-power wireless modules that extend sensor performance, while contract manufacturing organizations offer flexible scale-up capabilities and geographic diversification that many OEMs leverage to optimize cost and continuity of supply.

Distribution and service partners-ranging from specialty pharmacies to digital therapeutics providers-play a pivotal role in patient onboarding, adherence programs, and reimbursement navigation. These partners help translate device performance into sustained clinical outcomes by delivering education, remote monitoring services, and support infrastructures that reduce abandonment. Competitive intensity is thus shaped not only by hardware and software prowess but by the ability to orchestrate an ecosystem that eases access to devices, simplifies reimbursement, and demonstrates longitudinal clinical benefit.

Recommend integrated strategic actions for product development, supply chain resilience, payer engagement, and ecosystem partnerships to drive adoption and competitive differentiation

Industry leaders seeking to strengthen market position should prioritize an integrated approach that spans product design, data capabilities, and supply chain resilience. First, investing in durable sensor chemistry and intuitive user experience reduces friction for sustained use and improves retention. Combining hardware improvements with robust, regulatory-grade software that offers actionable insights enhances perceived value among clinicians and payers, supporting broader clinical adoption.

Second, diversifying manufacturing footprints and formalizing strategic relationships with contract manufacturers and regional partners will mitigate exposure to geopolitical and tariff-related disruptions. Near-term procurement flexibility can be achieved by multi-sourcing critical components and maintaining safety stock levels for high-demand items, while longer-term resilience benefits from investments in local production and automation.

Third, align commercial models with payer evidence requirements by embedding real-world outcomes collection into post-market activities. Collaborations with health systems to document reductions in acute events, hospital utilization, or clinical workflow efficiencies can strengthen reimbursement cases. Similarly, partnering with pharmacies and digital care providers to create bundled solutions and subscription models can lower access barriers and improve continuity of care.

Finally, cultivate interoperability and developer ecosystems to expand the utility of data streams. Open APIs, secure data exchange, and partnerships with electronic health record and telehealth vendors amplify clinical integration and create opportunities for differentiated services such as predictive analytics, population health management, and personalized coaching programs.

Describe a robust mixed-methods research approach combining secondary evidence, expert interviews, and triangulation to validate clinical, regulatory, and commercial insights

The research methodology combines systematic secondary research, primary industry engagement, and rigorous data synthesis to ensure findings are grounded in multiple evidence streams. Secondary research involved reviewing peer-reviewed clinical literature, regulatory filings, product labeling, and public policy documents to establish the scientific and regulatory context for device performance and approval pathways. Market activity and patent landscapes were examined to identify technology trends and innovation trajectories.

Primary research comprised expert interviews with clinicians, procurement leaders, product development executives, and distribution partners to capture firsthand perspectives on adoption barriers, operational challenges, and unmet clinical needs. These interviews were supplemented by consultations with regulatory specialists to validate interpretations of device classifications and post-market requirements. The qualitative insights obtained were then cross-checked against published clinical studies and company filings to maintain consistency.

Data synthesis used triangulation techniques that reconcile differing inputs and highlight consensus findings versus divergent viewpoints. Quality control procedures included source validation, methodological auditing by independent reviewers, and iterative feedback loops with subject-matter experts to refine assumptions and contextualize results within current industry practice. Ethical considerations were observed in primary engagements, with interviewees participating under confidentiality terms and data anonymization protocols where appropriate.

Summarize how technological innovation, evidence generation, and supply resilience must align to translate continuous glucose monitoring into scalable clinical and economic value

Continuous blood glucose monitoring systems represent a pivotal technology at the intersection of patient-centered care, digital health, and supply chain innovation. The collective trends observed-advances in sensor performance, software-driven differentiation, evolving reimbursement frameworks, and region-specific commercialization dynamics-underscore that success requires an ecosystem view rather than a sole focus on hardware specifications.

Stakeholders must navigate a landscape in which regulatory clarity, data integration, and evidence generation increasingly determine market access and clinical uptake. Supply chain complexities, amplified by tariff adjustments and geopolitical shifts, compel organizations to broaden sourcing strategies and accelerate investments in manufacturing agility. Meanwhile, end-user demands for simplicity, reliability, and clinically meaningful insights create pressure to deliver solutions that integrate seamlessly into daily life and clinician workflows.

The path forward favors organizations that combine technological excellence with strategic partnerships, payer-aligned evidence programs, and resilient operational models. By aligning product roadmaps with clinician needs and payer expectations, and by investing in interoperability and user experience, manufacturers and partners can expand access to continuous monitoring and improve outcomes for diverse patient populations. Ultimately, continuous monitoring will be judged not only by sensor accuracy but by its ability to drive sustained clinical benefit at scale.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of implantable continuous glucose monitors with extended wear time and minimal calibration
• 5.2. Integration of continuous glucose monitoring with mobile health apps for predictive glycemic insights
• 5.3. Expansion of remote patient monitoring services leveraging CGM data for telehealth diabetes care
• 5.4. Development of non-invasive CGM technologies using optical and electromagnetic sensing methods
• 5.5. Rise of AI-driven algorithms in CGM platforms for automated insulin dosing recommendations
• 5.6. Collaborations between device makers and digital therapeutics firms to enhance patient adherence
• 5.7. Emergence of cost-effective CGM sensors to improve accessibility in emerging markets
• 5.8. Regulatory approvals of next-generation CGM systems with tighter glucose accuracy standards
• 5.9. Increasing integration of CGM data into electronic health records for unified clinician workflows
• 5.10. Personalized glycemic forecasting tools based on machine learning models trained on CGM datasets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Continuous Blood Glucose Monitoring Systems Market, by Technology

• 8.1. Real Time CGM
  • 8.1.1. Personal Real Time CGM
  • 8.1.2. Professional Real Time CGM
• 8.2. Retrospective CGM
  • 8.2.1. Professional Retrospective CGM

9. Continuous Blood Glucose Monitoring Systems Market, by Product

• 9.1. Data Management Software & Services
  • 9.1.1. Data Management Software
  • 9.1.2. Support Services
• 9.2. Sensor
• 9.3. Transmitter & Receiver
  • 9.3.1. Receiver
  • 9.3.2. Transmitter

10. Continuous Blood Glucose Monitoring Systems Market, by End User

• 10.1. Ambulatory Care Centers
  • 10.1.1. Diagnostic Centers
  • 10.1.2. Surgery Centers
• 10.2. Home Care
• 10.3. Hospitals & Clinics
  • 10.3.1. Clinics
  • 10.3.2. Hospitals

11. Continuous Blood Glucose Monitoring Systems Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
  • 11.2.1. E Commerce Websites
  • 11.2.2. Manufacturer Websites
• 11.3. Retail Pharmacies
  • 11.3.1. Chain Pharmacies
  • 11.3.2. Independent Pharmacies

12. Continuous Blood Glucose Monitoring Systems Market, by Application

• 12.1. Gestational Diabetes
• 12.2. Type 1 Diabetes
• 12.3. Type 2 Diabetes

13. Continuous Blood Glucose Monitoring Systems Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Continuous Blood Glucose Monitoring Systems Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Continuous Blood Glucose Monitoring Systems Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Dexcom, Inc.
  • 16.3.2. Abbott Laboratories
  • 16.3.3. Medtronic plc
  • 16.3.4. F. Hoffmann-La Roche Ltd
  • 16.3.5. Senseonics Holdings, Inc.
  • 16.3.6. Nipro Corporation
  • 16.3.7. ARKRAY, Inc.
  • 16.3.8. Sinocare Inc.
  • 16.3.9. Ypsomed Holding AG
  • 16.3.10. Medtrum Technologies Inc.